Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Ovid Therapeutics's share price for the quarter that ended in Mar. 2026 was $2.22. Ovid Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 167.27 Mil. Therefore, Ovid Therapeutics's market cap for the quarter that ended in Mar. 2026 was $371.33 Mil.
Ovid Therapeutics's quarterly market cap
increased
from Sep. 2025 ($92.50 Mil) to Dec. 2025 ($212.20 Mil) and
increased
from Dec. 2025 ($212.20 Mil) to Mar. 2026 ($371.33 Mil).
Ovid Therapeutics's annual market cap
declined
from Dec. 2023 ($227.63 Mil) to Dec. 2024 ($66.30 Mil) but then
increased
from Dec. 2024 ($66.30 Mil) to Dec. 2025 ($212.20 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Ovid Therapeutics's Enterprise Value for Today is $359.61 Mil.
Ovid Therapeutics (NAS:OVID) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Ovid Therapeutics Market Cap Related Terms
Ovid Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Ovid Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ovid Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovid Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Ovid Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Ovid Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ovid Therapeutics (OVID) has a Market Cap of $502.06 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ovid Therapeutics and its competitors. According to the industry distribution chart, Ovid Therapeutics ranks #411 out of 1427 companies in the Biotechnology industry, placing it in the top 28.8%.
Is Ovid Therapeutics' Market Cap too high?
Ovid Therapeutics' current Market Cap is $502.06 Mil. The Biotechnology industry median Market Cap is 119.57. Ovid Therapeutics' value of $502.06 Mil is 319.9% above this industry median. Based on the distribution chart, Ovid Therapeutics ranks #411 out of 1427 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ovid Therapeutics has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ovid Therapeutics' Market Cap compare to ARTV and CCCC?
According to the Biotechnology industry distribution chart, Ovid Therapeutics ranks #411 out of 1427 companies for Market Cap. This puts Ovid Therapeutics in the upper half of its industry. The industry median Market Cap is 119.57. Ovid Therapeutics' value of $502.06 Mil is 319.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.57, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ovid Therapeutics's current Market Cap of $502.06 Mil is 319.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ovid Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 119.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ovid Therapeutics's current Market Cap is $502.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovid Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ovid Therapeutics (OVID) is currently considered Possible Value Trap. The stock's GF Value™ is $8.46, compared to a current price of $2.69 — trading 68.2% below its estimated fair value. The current Market Cap is $502.06 Mil and 319.9% above the Biotechnology industry median of 119.57. Ovid Therapeutics' overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Ovid Therapeutics (OVID), the current Market Cap is $502.06 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ovid Therapeutics (OVID) Overvalued in 2026?
Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be undervalued.
The current stock price of $2.69 is trading 68.2% below its estimated GF Value™ of $8.46.
GuruFocus considers Ovid Therapeutics to be Possible Value Trap.
Key valuation signals for OVID:
Market Cap: $502.06 Mil
GF Value™: $8.46 vs. price of $2.69 (68.2% below fair value)
Industry Position: 319.9% above the Biotechnology median (#411 of 1427)
No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
48GF Score
Get the complete analysis for OVID
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OVID has been successfully added to your 
